AzTrials
AzTrials

Aortic Aneurysm, AbdominalNCT01654133

Evaluation of Visceral Function Following Endovascular Aortic Aneurysm Repair Using Branched Stent- Grafts

A study testing Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft and Endovascular repair of ascending/arch aortic aneurysm using branched stent graft in people with Aortic Aneurysm, Abdominal and Ascending Aorta Aneurysm, run by University of North Carolina, Chapel Hill at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to evaluate visceral function, after endovascular repair of thoracoabdominal aneurysms or ascending/aortic arch aneurysms. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft and Endovascular repair of ascending/arch aortic aneurysm using branched stent graft
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
770 participants
Where
1 siteUnited States
Study dates
Jul 2012to Aug 2035
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • General Exclusion Criteria
  • Patients must be excluded from the study if any of the following conditions are true:
  • Less than 18 years of age
  • Unwilling to comply with the follow-up schedule
  • Inability or refusal to give informed consent
  • Medical Exclusion Criteria
Show all 75Show fewer
  • Patients must be excluded from the study if any of the following conditions are true:
  • 1) Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin, silver), polypropylene, urethane or gold 2) History of anaphylactic reaction to contrast material that cannot be adequately premedicated 3) Leaking, ruptured aneurysm associated with hypotension 4) Uncorrectable coagulopathy
  • Anatomical Exclusion Criteria
  • Patients must be excluded from the study if any of the following conditions are true:
  • Inadequate femoral/iliac access compatible with the required delivery systems;
  • Does not have a non-aneurysmal aortic segment proximal to the aneurysm with:
  • A length of at least 4 mm, i.e. at least 4 mm circumferential wall contact around the limits of scallop b. A diameter measured outer wall to outer wall of no greater than 31mm and no less than 21 mm; c. An angle less than 60 degrees relative to the centerline of the aneurysm; d. An angle less than 45 degrees relative to the supraceliac aorta.
  • Does not have visceral vessel anatomy compatible with Zenith® p-Branch™, specifically:
  • Renal vessel origins as measured relative to the superior mesenteric artery (SMA) compatible with the renal fenestration, i.e. Both renal vessel origins within 7.5mm of the corresponding renal fenestrations; b. Celiac vessel origin as measured relative to the superior mesenteric artery (SMA) compatible with the celiac scallop.
  • A proximal seal site with unsuitable thrombus/atheroma
  • Does not have iliac artery fixation sites and anatomy consistent with:
  • Common iliac artery fixation site diameter, measured outer wall to outer wall on a sectional image (CT) <8.0 mm (prior to deployment)
  • Iliac artery diameter, measured outer wall to outer wall on a sectional image (CT) >21 mm at distal fixation site
  • Iliac artery distal fixation site <10 mm in length
  • Inability to preserve at least one hypogastric artery
  • -
  • Cohort 2 (ascending/aortic arch) Inclusion Criteria:
  • General Inclusion Criteria:
  • Treatment not possible with a currently available non-modified approved device
  • Patient accepts to and is able to comply with lifetime follow-up
  • Patient accepts to and is able to provide informed consent prior to enrollment
  • No stroke with significant residual deficit or myocardial infarction within the last 12 months
  • No significant carotid bifurcation disease (> 70% stenosis by NASCET criteria)
  • Absence of systemic or local infection that may increase the risk of endovascular graft infection
  • Patient determined to be a high-risk profile for open surgical repair considering any of the following items:
  • Anatomy: previous sternotomy or left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta), previous aortic surgery, large aneurysm abutting the sternum with risk of disruption during sternotomy, prior cervical or chest irradiation.
  • Physiology: ASA Category ≥ III, age >70 years, previous myocardial infarction, coronary artery disease, or coronary artery stent, coronary stress test with a reversible perfusion defect, COPD, congestive heart failure
  • Vascular Inclusion Criteria:
  • Aortic Aneurysm Diameter: Ascending and/or Arch aneurysm with or without aortic or aortoiliac aneurysm with orthogonal aortic diameter greater than two times the normal aortic diameter
  • Rapid aortic enlargement (≥ 5 mm in 1 year)
  • Presence of a saccular aneurysm at risk for rupture based on the investigators evaluation
  • Clinical indication for aneurysm repair based on symptoms
  • Concomitant thoracoabdominal and aortic arch aneurysm meeting one of the above-mentioned criteria.
  • Anatomic Inclusion Criteria:
  • 1) There is enough space for the device to be deployed distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion 2) Ascending aortic length >50 mm (greater curve distance from sinotubular junction to proximal aspect of the innominate artery) 3) Sealing zone in the ascending aorta >40 mm in length and <38 mm in diameter for native aorta (<42 mm if surgical graft replacement in place) 4) Sealing zone in the great vessels of >20 mm in length
  • Diameter of innominate artery used for sealing < 20 mm
  • Diameter of CCA or subclavian artery used for sealing < 16mm 5. Distal aortic fixation zone: Native aorta or surgical graft (endovascular device or Dacron graft) , diameter: 20-42mm, distal neck length ≥20mm 6) Access for device delivery to accommodate 22F or 24F sheath depending on device design.
  • 7) Sealing zone in the great vessels of ≥ 20 mm in length
  • Diameter of innominate artery used for sealing between 8 and 20 mm
  • Diameter of CCA or subclavian artery used for sealing between 6 and 16 mm.
  • Extra inclusion criteria - special situations:
  • Aortic dissection:
  • A true lumen size large enough for device deployment and to gain access into the target branches
  • A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, so that the graft would seal off the dissection lumen
  • A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection or surgically created
  • Access into the true lumen from the groin and to at least one supra-aortic trunk vessel
  • If more distal disease is observed in the aorta
  • The repair might be coupled with a thoracoabdominal branched device
  • Iliac anatomy large enough to allow the delivery of the arch branch device which is loaded within a 20F-24F sheath. Iliac conduits may be set in place if necessary.
  • General exclusion criteria:
  • Life expectancy less than 2 years
  • Less than 18 years of age
  • Women must not be pregnant or breastfeeding
  • Active malignancy with life expectancy less than 2 years
  • Presence of mycotic aneurysm, systemic or local infection in access sites that may increase the risk of endovascular graft infection
  • Untreatable coagulopathy
  • Coronaropathy / Unstable angina
  • Anaphylactic reaction to contrast that cannot be adequately pre-medicated
  • Cultural objection to receipt of blood or blood products
  • Allergy or sensitivity to the endografts material (stainless steel, polyester, polypropylene, solder (tin, silver), gold, or nitinol)
  • Leaking or ruptured aneurysm associated with hypotension
  • Participation in another investigational clinical or device trial, except for participation in another investigational endovascular stent-graft protocol, percutaneous aortic valve protocol, or concomitant clinical trials designed to evaluate medical therapy strategies to reduce perioperative risk during fenestrated-branched endovascular repair
  • Prior open surgical or interventional procedure within 30 days of the anticipated date of the fenestrated-branched procedure, with the exception of planned procedures to provide access for repair (e.g. staged iliac conduit, cervical debranching) or to facilitate the procedure.
  • Anatomic Exclusion Criteria for the Cook Ascending/Arch graft
  • Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access.
  • Iliac artery diameter, measured inner wall to inner wall on a sectional image (CT) <7.0 mm at any point along access length (prior to deployment). Inability to perform a temporary or permanent open surgical or endovascular iliac conduit for patients with inadequate femoral/iliac access.
  • Proximal seal length < 40 mm
  • Proximal seal site with a circumferential thrombus/atheroma/calcium
  • -

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site

  • UNC Heart and Vascular

    Chapel Hill, North Carolina, 27599

Other trials in United States

About this study

The purpose of this study is to evaluate visceral function, after endovascular repair of thoracoabdominal aneurysms or ascending/aortic arch aneurysms.

Read the detailed description

This study will evaluate the effect of endovascular repair of thoracoabdominal aortic aneurysms (Types I-IV) on visceral function or aortic arch aneurysms using custom manufactured and off the shelf stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function. Since detailed CT scan imaging will be performed prior to and after endovascular repair, critical data concerning each branched vessel length, tangential orientation from the aorta, angle of incidence, and diameter can be determined. This information can then be coupled with hemodynamic data obtained from duplex ultrasonography as well as changes in renal volume, estimated glomerular filtration rate (eGFR), and flow characteristics over time. By analyzing the data in this fashion, it may be possible to determine changes in hemodynamics and/or physiologic conditions with respect to branched stent-graft design characteristics. These data may be utilized to enhance current device design and improve patient outcomes. The FDA has approved the use of commercially available devices to be used in conjunction with the investigational device if the Investigator deems this necessary.

Being tested
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft, Endovascular repair of ascending/arch aortic aneurysm using branched stent graft
Keywords
Aortic Aneurysm, abdominal, Ascending Aorta Aneurysm, Aortic Arch Aneurysm
Medical subject headings
Aortic Aneurysm, Abdominal, Aneurysm, Ascending Aorta, Aneurysm, Aortic Arch

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graftDevice

    Also called Endovascular repair of thoracoabdominal aortic aneurysm

    Repair of thoracoabdominal aortic aneurysms

  • Endovascular repair of ascending/arch aortic aneurysm using branched stent graftDevice

    Also called Endovascular repair of ascending/ arch aortic aneurysm

    Repair of ascending/arch aortic aneurysms

Study groups in NCT01654133
Study groupRoleWhat they receive
Endovascular TAAA RepairExperimentalEndovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
Receives: Device: Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft
Endovascular Ascending/Aortic Arch Branch RepairExperimentalEndovascular repair of aortic ascending/arch aneurysm using branched stent grafts
Receives: Device: Endovascular repair of ascending/arch aortic aneurysm using branched stent graft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair various custom stent grafts

    Visceral function after endovascular repair of pararenal aneurysms using various custom stent grafts. Specifically, the device orientation and configuration will be evaluated with respect to renal function over time. Critical data concerning each branched vessel from radiological studies coupled with hemodynamic data obtained from renal artery duplex, changes in renal volume, eGFR, and flow characteristics at 1, 6, 12, 18 and 24 months post procedure may make it possible to determine changes in renal function.

    Measured: Pre-procedure and 1, 6, 12, 18, and 24 months post procedure

Secondary outcomes (6)

  1. Time to morbidity

    Morbidity at 30 days, 1 \& 2 years post procedure

    Measured: 30 days and 1 & 2 years post procedure

  2. Time to mortality

    Mortality at 30 days, 1 \& 2 years post procedure.

    Measured: 30 days and 1 & 2 years post procedure

  3. Time to loss of stent graft integrity

    Evidence on contrast CT angiography of loss of stent graft integrity at 30 days, and one and two years post procedure.

    Measured: 30 days and 1 & 2 years post procedure

  4. Time to migration

    Evidence of stent graft migration on abdominal x-rays at 30 days and 1 \& 2 years.

    Measured: 30 days and 1 & 2 years post procedure

  5. Endoleak

    Evidence of Endoleak on contrast CT angiography of abdomen 30 days and 1 \& 2 years post procedure.

    Measured: 30 days and 1 & 2 years post procedure

  6. Branch vessel Events

    Evidence of branch vessel events on contrast CT angiography and renal duplex 30 days, and 1 \& 2 years post procedure.

    Measured: 30 days and 1 & 2 years post procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2012 (estimated)
  2. Study startJul 2012
  3. Primary completionAug 2035 (estimated)
  4. Study completionAug 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
770 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01654133
Sponsor's protocol ID
12-0644
Status last verified
Apr 2026
First submitted
27 Jul 2012
Last updated
15 Apr 2026
Results posted
No
Data monitoring committee
Yes

Publications

  • Mesnard T, Huang Y, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Parodi FE, Gasper WJ, Beck AW, Sweet MP, Zetterval SL, Lee A, Oderich GS; United States Aortic Research Consortium. Multicenter Prospective Evaluation of Patient Radiation Exposure During Fenestrated-branched Endovascular Aortic Repair: A Ten-year Experience. Ann Surg. 2026 Jul 1;284(1):184-193. doi: 10.1097/SLA.0000000000006676. Epub 2025 Feb 18.

    PubMed 39963789

  • Oderich GS, Huang Y, Harmsen WS, Tenorio ER, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Gasper WJ, Beck AW, Sweet MP, Lee WA; United States Aortic Research Consortium. Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study. Circulation. 2024 Oct 22;150(17):1343-1353. doi: 10.1161/CIRCULATIONAHA.123.068234. Epub 2024 Jul 11.

    PubMed 38989575

  • Finnesgard EJ, Beck AW, Eagleton MJ, Farber MA, Gasper WJ, Lee WA, Oderich GS, Schneider DB, Sweet MP, Timaran CH, Simons JP, Schanzer A; United States Aortic Research Consortium. Severity of acute kidney injury is associated with decreased survival after fenestrated and branched endovascular aortic aneurysm repair. J Vasc Surg. 2023 Oct;78(4):892-901. doi: 10.1016/j.jvs.2023.05.034. Epub 2023 Jun 16.

    PubMed 37330702

  • Aucoin VJ, Motyl CM, Novak Z, Eagleton MJ, Farber MA, Gasper W, Oderich GS, Mendes B, Schanzer A, Tenorio E, Timaran CH, Schneider DB, Sweet MP, Zettervall SL, Beck AW; U.S. Aortic Research Consortium. Predictors and outcomes of spinal cord injury following complex branched/fenestrated endovascular aortic repair in the US Aortic Research Consortium. J Vasc Surg. 2023 Jun;77(6):1578-1587. doi: 10.1016/j.jvs.2023.01.205. Epub 2023 Apr 13.

    PubMed 37059239

Questions about this trial

What is this clinical trial studying?

A study testing Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft and Endovascular repair of ascending/arch aortic aneurysm using branched stent graft in people with Aortic Aneurysm, Abdominal and Ascending Aorta Aneurysm, run by University of North Carolina, Chapel Hill at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 75 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair various custom stent grafts (time frame: Pre-procedure and 1, 6, 12, 18, and 24 months post procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01654133, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in